Memantin Pliva

Memantine Hydrochloride, the active ingredient in Memantin Pliva, is a non‑competitive NMDA receptor antagonist presented as an oral dosage form for oral administration. It is used to treat moderate to severe Alzheimer’s disease, helping to improve cognition and functional abilities in adult patients diagnosed with this neurodegenerative condition.

GNH USA supplies Memantin Pliva as a licensed, GDP‑compliant international pharmaceutical supplier, sourcing the product from EU manufacturers and delivering it to hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support safe use.

Memantin Pliva is indicated for conditions involving neurodegeneration where NMDA receptor over‑activity contributes to cognitive decline.

Alzheimer’s disease (moderate to severe): Improves cognition, daily functioning, and may slow symptom progression in adult patients. Behavioral disturbances associated with Alzheimer’s disease: May help reduce agitation, aggression, and improve overall patient behavior.

Memantin Pliva may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Hypertension - Insomnia

Serious or Rare Side Effects: - Seizures - Cardiac arrhythmia - Hepatic dysfunction - Severe allergic reactions (e.g., Stevens‑Johnson syndrome) - Psychosis or severe agitation - Suicidal thoughts or behavior

When prescribing Memantin Pliva, clinicians should consider several safety measures. - Dose titration: Initiate at low dose and increase gradually as tolerated. - Renal impairment: Adjust dose in patients with reduced kidney function. - Hepatic impairment: Use with caution in liver disease. - Concomitant NMDA antagonists: Avoid combining with other NMDA blockers. - Psychiatric history: Monitor for worsening depression or suicidal ideation. - Store at room temperature: Keep in original container, protect from moisture and light.

Memantin Pliva can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Amantadine: May increase risk of neurotoxicity. - Ketamine: Additive NMDA antagonism can cause excessive CNS depression. - High‑dose zinc supplements: May reduce memantine absorption.

Moderate Interactions (Monitor Closely): - Anticholinesterases (donepezil, rivastigmine): May blunt therapeutic effect. - Diuretics (furosemide): May increase plasma levels of memantine. - CNS depressants (benzodiazepines): May enhance sedation.